Abstract
The impact of mapping the human proteomeGlobally, the health care organizations are under resource and cost constrains due to the increasing number of patients that are due to a fast increase of the 65+ age group requiring extensive medical hospitalization and treatments. Hospitals worldwide strive to seek the best cure for patients, suffering from various diseases. A consequence of these global changes, of healthy populations in relation to patients forms the basis for the build of large and centralized biobank facilities, with strategies where the search for an understanding of diseases at a molecular level is at heart. The efforts made lies within large governmental resource allocations where patient centers are collecting samples from clinical study participants in order to try to discover universal expression patterns and molecular signatures of disease and disease stages. Most developments in this area are aimed towards the discovery, and understanding diagnosis implementations. By providing the right treatment alternatives for patients care, at the right time point i.e., at a given disease stage development becomes a major goal where pharmaceutical industry, academia and the health care sector joins forces in large clinical epidemiological, population-, and disease based studies. This becomes a clear strategic link to the enhancement and prospects for personalized medicines and target directed diagnosis developments (Companion Diagnostics), which require coordinated efforts across a wide range of disciplines. Currently, companion diagnostics is at the core of the personalized medicine paradigm shift. It will identify patients who are most likely to benefit from a particular therapeutic product, as well as identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic agent. It is predicted that more than half of all new drugs will require a companion diagnostic, which opens up for an endeavor for Proteomics research implementations.
Highlights
BioBanking Archive mRNAThe current status of healthcare requests and demands can be summarized by that currently more than 7,000 rare diseases affect human mankind and less than 200 have available pharmacotherapy [8]
The impact of mapping the human proteome: Globally, the health care organizations are under resource and cost constrains due to the increasing number of patients that are due to a fast increase of the 65+ age group requiring extensive medical hospitalization and treatments
The consequence is that large clinical epidemiological, population, and disease based studies are undertaken to get an overall higher efficacy as well as an improved safety assessment where Companion Diagnostics will play a major role [3,4,5]
Summary
The current status of healthcare requests and demands can be summarized by that currently more than 7,000 rare diseases affect human mankind and less than 200 have available pharmacotherapy [8]. Considering an estimated number of 20,300 proteins within the Human Proteome, coded by the genome, will increase and reach into several million proteins after cellular processing, the key protein targets to be considered is a real challenge. The C-HPP consortia deliveries over the coming years will be instrumental in these development programs. These difficult healthcare issues will entail large number of biobank samples with ample statistical power. Worldwide biobank archives will need to work together
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
